There are 3484 resources available
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1304P - A structured multidisciplinary approach for diagnosing immune-related pneumonitis in patients undergoing adjuvant durvalumab for stage III non-small cell lung cancer
Presenter: Illaa Smesseim
Session: Poster session 04
316P - Comprehensive characterization of the HER2-enriched intrinsic molecular subtype in ER-positive HER2-negative breast cancer
Presenter: Lennart Hohmann
Session: Poster session 02
615P - The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Presenter: Satoshi Yuki
Session: Poster session 10
2240P - Novel genetic markers associated with immune checkpoint inhibitor induced immune-related adverse events
Presenter: Ik Shin Chin
Session: Poster session 07
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1305P - Importance of the resected lung tumor specimen in patients with locally advanced and metastatic non-small cell lung cancer undergoing prior targeted therapy
Presenter: Jeong Uk Lim
Session: Poster session 04
317P - Awareness of genomic testing among patients with breast cancer in Europe
Presenter: Antonella Cardone
Session: Poster session 02
616P - Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Presenter: Tanios Bekaii-Saab
Session: Poster session 10